A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 Administered Daily for 28 Days to Patients with Advanced Solid Tumors

IRB/UVA Tracking #
21503
Contact
Stephen Hazen
Contact Phone
Phase
I
Primary purpose
Treatment
Cancer PI
Patrick M Dillon
Status
OPEN TO ACCRUAL
Ages
Adult